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The Cancer Genome Atlas (TCGA) project has gener-
ated gene expression data that divides glioblastoma
(GBM) into four transcriptional classes: proneural,
neural, classical, and mesenchymal. Because tran-
scriptional class is only partially explained by under-
lying genomic alterations, we hypothesize that the
tumor microenvironment may also have an impact.
In this study, we focused on necrosis and angiogene-
sis because their presence is both prognostically and
biologically significant. These features were quanti-
fied in digitized histological images of TCGA GBM fro-
zen section slides that were immediately adjacent to
samples used for molecular analysis. Correlating
these features with transcriptional data, we found
that the mesenchymal transcriptional class was sig-
nificantly enriched with GBM samples that contained
a high degree of necrosis. Furthermore, among 2422
genes that correlated with the degree of necrosis in
GBMs, transcription factors known to drive the mes-
enchymal expression class were most closely related,
including C/EBP-, C/EBP-, STAT3, FOSL2, bHLHE40,
and RUNX1. Non-mesenchymal GBMs in the TCGA
data set were found to become more transcriptionally
similar to the mesenchymal class with increasing lev-
els of necrosis. In addition, high expression levels of
the master mesenchymal factors C/EBP-, C/EBP-,
and STAT3 were associated with a poor prognosis.
Strong, specific expression of C/EBP- and C/EBP-
by hypoxic, perinecrotic cells in GBM likely account
for their tight association with necrosis and may be
2108related to their poor prognosis. (Am J Pathol 2012, 180:
2108–2119; DOI: 10.1016/j.ajpath.2012.01.040)
Glioblastoma (GBM) (World Health Organization, grade
IV) is the most common and highest grade astrocy-
toma.1,2 Currently incurable, it has a mean survival that
only slightly exceeds 1 year following standard surgical
and adjuvant therapies.3 Analyses of large scale gene
expression and genomic datasets have indicated that
this disease represents multiple molecular subclasses,
raising the possibility that future therapies could be di-
rected at underlying class-specific mechanisms. Phillips
et al4 and Verhaak et al5 have each shown that unsuper-
vised clustering of GBM gene expression profiles results
in three or four distinct transcriptional classes.
Epigenetic changes and genetic alterations, including
mutations, amplifications, and deletions of established
tumor suppressors and oncogenes, account for at least
some transcriptional class identity of GBM. For example,
among The Cancer Genome Atlas (TCGA) tumors, which
contain proneural, neural, classical, and mesenchymal
transcriptional classes, IDH1 mutations and the CpG is-
land methylator phenotype (G-CIMP) are seen almost
exclusively in the proneural transcriptional class,
whereas nearly all tumors with NF1mutations or deletions
are within the mesenchymal class.5–7 However, some of
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cluding TP53 and PTEN mutation, EGFR and PDGFR am-
plification and CDKN2A deletion are noted in multiple
transcriptional classes, indicating that cell-intrinsic ge-
netic defects only partially explain the class-specific
gene expression patterns.
A recent analysis of GBM expression classes used a
novel algorithm to reconstruct transcriptional interactions
and uncovered a small set of transcription factors that reg-
ulate the transition to the mesenchymal class, including
C/EBP-, C/EBP-, STAT3, FOSL2, bHLHE40, and RUNX1.
Among these, C/EBP-, C/EBP-, and STAT3 were found to
be master transcriptional regulators, controlling the expres-
sion of other key regulators, and accounting for the majority
of downstream signaling events and the mesenchymal
gene signature.8 Underlying genetic alterations or patho-
physiological triggers of these master transcriptional regu-
lators were not uncovered. It remains possible that ele-
ments of the tumor microenvironment, including tumor
hypoxia, necrosis, angiogenesis, or inflammatory cell in-
filtrates, could strongly impact both transcriptional regula-
tors and gene expression class. Microenvironmental contri-
butions to expression class, as well as the tissue sampling
considerations that are intimately related, will need to be
carefully considered asmolecular profiles are used to direct
therapies.
To address these issues, we performed an integrated
morphological and molecular analysis of microenviron-
mental factors as they relate to GBM transcriptional class.
We analyzed gene expression and genetic correlates of
angiogenesis and necrosis in GBM using molecular data
and the digitized images from corresponding frozen sec-
tions used for quality assurance by the TCGA. We found
that the mesenchymal class of GBM was enriched with
samples displaying a high degree of necrosis, and that
the expression of transcriptional regulators of the mesen-
chymal transition, C/EBP-, C/EBP-, STAT3, FOSL2,
bHLHE40, and RUNX1, were tightly correlated with the
extent of necrosis. Nonmesenchymal GBMs became more
transcriptionally similar to the mesenchymal class with in-
creasing levels of necrosis. Using human GBM tissue sec-
tions, we demonstrated that C/EBP- and CEBP- were
specifically expressed by hypoxic, peri-necrotic pseudo-
palisading cells, accounting for the association of these
factors with necrosis. Our finding that the high expression of
C/EBP-, C/EBP-, and STAT3 portends a poor prognosis
suggests that these key signaling nodes may hold potential
for targeted therapies.
Materials and Methods
Digitized Images used for Morphological Analysis
A complete description of samples, and related imaging,
molecular, and pathology data are provided in Supple-
mental Tables 1–6 (available at http://ajp.amjpathol.org).
Whole-slide digitized images of GBM frozen sections
were obtained from the TCGA portal (http://tcga-data.
nci.nih.gov/tcga/tcgaHome2.jsp; last accessed June 6,
2011). Frozen section slides were scanned and digitizedat 20 resolution on an Aperio scanner at the TCGA
Biospecimen Core Resource located at the International
Genomics Consortium (Intgen, Phoenix, AZ). The frozen
section slides were those reviewed by Intgen contracted
neuropathologists for quality assurance to ensure that the
tissue between the top section and bottom section were
adequate for molecular studies. Importantly, the tissue
used for molecular analysis by TCGA was immediately
adjacent to the tissue used to create slides for this inves-
tigation. We used these digitized images as our primary
source of data and annotated necrosis on 177 slides from
99 samples corresponding to 91 patients. Angiogenesis
was annotated on 168 slides from 95 samples corre-
sponding to 88 patients. As a secondary source of data
on necrosis in GBM samples, we used semi-quantitative
annotations of 293 GBMs that were recorded by TCGA
neuropathologists after reviewing frozen section slides for
quality assurance. For these images, the percent necrosis
was recorded as a visual estimate of total tissue area in-
volved. Angiogenesis was recorded only as “present” or
“absent” and was not useful in our analysis. There were 70
samples with overlap between the two sources of data.
Quantification of Percent Necrosis and
Angiogenesis in GBM Samples
Regions of necrosis and angiogenesis were manually out-
lined using ImageScope software (Aperio, Vista CA) by two
pathologists working together and reaching a consensus on
the features to include (CA, DJB).9 The boundaries of tissue
sections were outlined to calculate total tissue area. Dupli-
cate adjacent sections within the same slide were not ana-
lyzed. Regions identified as either necrosis or angiogenesis
were exhaustively outlined within the tissue boundaries (Fig-
ure 1). Angiogenic regions were identified as those vascular
regions departing from normal, and exhibiting characteris-
tics of cellular hypertrophy, cellular hyperplasia, or micro-
vascular proliferation.1,10,11 In addition to the endothelial
compartment, the perivascular cells, including pericytes,
fibroblasts, and any inflammatory infiltrates, were included
within marked angiogenic regions. Luminal areas were au-
tomatically subtracted from angiogenic regions using com-
puter-based color segmentation. The extent of necrosis and
the extent of angiogenesis were calculated as a percentage
of whole tissue by taking the ratios of necrosis or angiogen-
esis surface areas to the total tissue section area. Areas
were summed over multiple slides before ratio calculation to
determine per-sample and per-patient percentages.
Correlation of Necrosis and Angiogenesis with
GBM Transcriptional Class, Copy Number
Alterations, Gene Expression, and Methylation
Status
Transcriptional class labels for TCGA patients were ob-
tained from the TCGA Advanced Working Group. This
labeling extends the original set of samples labeled by
Verhaak et al5 using Affymetrix HT_HG-U133A data to
classify previously unlabeled TCGA samples given cen-
troids derived from the original labeled set. Patient-re-
crosis w
ence in
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tested for association with transcriptional class with one-
way analysis of variance tests. Copy number data were
obtained from the GBM Pathway analysis at the Memorial
Sloan Kettering Cancer Genomics Portal (http://www.
cbioportal.org/public-portal; last accessed June 6, 2011).
Level 3 sequence data obtained from the TCGA portal
was filtered to remove silent mutations. Necrosis was
compared between amplified/normal, deleted/normal, and
mutant/wild-type samples using two-way t-tests. Level 2
robust multichip average normalized gene expression data
from the Affymetrix U133A platform was averaged over
samples with multiple arrays to create patient-reduced ex-
pression profiles. Probes with an unlogged expression
range of 20 and a fold change of 1.5 were removed.
Percentage necrosis and angiogenesis were correlated
with expression profiles using the Cox proportional hazards
within the significance analysis of microarray procedure.12
Gene-centric profiles of C/EBP-, C/EBP-, and STAT3
were obtained by averaging over the corresponding
probes. Methylation phenotype G-CIMP status was calcu-
lated, as previously described.7,13
Pathway Analysis
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, Red-
wood City, CA) was applied to gene lists generated by
significance analysis of microarray analysis of necrosis and
angiogenesis, as previously described.13 Both direct and
Figure 1. Representative examples of The Cancer Genome Atlas (TCGA)
angiogenesis and the distribution of cases within TCGA gene expression clas
line surrounds regions of necrosis in (A, B) and the pink line surrounds the
vessels in (D, E) and the green line represents the lumen, which is subtracte
lines within each category represent the mean value. The mean value of ne
analysis of variance, P  8.7e-4). There was no statistically significant differindirect relationships were included. Data sources wererestricted to human species and cell lines. Network signifi-
cance was assigned by hypergeometric scoring.
Correlation of Macrophages with GBM
Transcriptional Class and Gene Expression
We obtained TCGA neuropathologists ratings of patho-
logical categories for 112 GBM samples with either gene
expression or transcriptional class assignments (http://
tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp; last accessed
June 6, 2011). Association between transcriptional class
and the presence of macrophages (0, 1, or 2) was
performed using Fisher’s test. Expression differences for
C/EBP-, C/EBP-, and STAT3 were examined using two-
way t-tests with unequal variance.
Mesenchymal Signature Analysis
The mesenchymal signature was calculated using the
classification to nearest centroid procedure.14 A set of
250 probes that distinguish mesenchymal samples were
selected by ranking t-statistics computed by comparing
sample-reduced expression profiles of mesenchymal
and nonmesenchymal samples. The mesenchymal sig-
nature was calculated as the average expression of these
250 probes of all mesenchymal sample profiles. Tran-
scriptional distance of each nonmesenchymal sample to
the mesenchymal signature was calculated as the Euclid-
stoma (GBM) frozen sections marked up for (A, B) necrosis and (D, E)
d on their percent necrosis (C) and percent angiogenic vessels (F). The blue
ssue and represents the total tissue area. The red line surrounds angiogenic
he vessel area. Each dot in (C, F) represents a GBM sample. Solid horizontal
as larger in the mesenchymal class than in the other three classes (one-way
mean angiogenic areas among expression classes.gliobla
ses base
entire ti
d from tean distance normalized by the SD of each probe. Cor-
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crosis were calculated using Spearman rank correlation.
Immunohistochemistry
Ten archived surgically resected GBM specimens were
retrieved from Emory University Hospital Department of
Pathology. These GBMs had not been previously treated
with radiation or chemotherapy and blocks contained
regions of high-grade glioma with foci of necrosis, infil-
trating glioma, and adjacent non-neoplastic brain. GBM
tissues were fixed in 10% buffered formalin, routinely
processed, and paraffin-embedded. Immunohistochem-
ical (IHC) studies were performed on 6-m sections as
described.15,16 Sections were deparaffinized and sub-
jected to heat-induced epitope retrieval by steaming for
15 minutes. Slides were then incubated with antibodies
directed toward Stat3 (rabbit polyclonal, 1:100; Cell Sig-
naling, Beverly, MA) and phospho-Stat3 (rabbit poly-
clonal, 1:100; Abcam, Cambridge, MA), C/EBP- (mono-
clonal, 1:100; Abcam), C/EBP- (polyclonal, 1:100,
Novus Biologicals, Littleton, CO), CD68 (monoclonal,
1:100; Biocare Medical, Concord, CA), and CD163
(polyclonal, 1:100; Novus Biologicals). Antibodies
were detected using the avidin-biotin-peroxidase com-
plex method using 3,3=-diaminobenzidine as the chro-
mogen. Normal sera served as the negative control.
Sections were counterstained with hematoxylin.
Glioblastoma Cell Lines and Culture Conditions
Human GBM cell line U87MG cell culture conditions have
been previously described.15,16 Cells used in experi-
ments were grown to 80% confluence in 100-mm culture
dishes, placed in serum free media in conditions of 21%
O2 (normoxia) or 1%O2 (hypoxia)
17,18
. For experiments in
1% O2, culture dishes were placed in incubators that are
dedicated to hypoxia (94% N2, 5% CO2, and 1% O2 at
37°C). Exposure to hypoxia lasted 24 hours.
Western Blot Analysis
Immunoblots were performed on proteins from cell ly-
sates of the indicated cell lines. The NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Pierce Biotechnology,
Rockford, IL) was used for separation of nuclear and
cytoplasmic protein fractions. Protein concentrations
were determined by a Bradford assay (Bio-Rad Labora-
tories, Hercules, CA). Equal amounts of protein (30 g)
were resolved on a 10% SDS-PAGE and transferred to
nitrocellulose membranes. Blots were incubated in block-
ing solution (PBS containing 0.02% Tween-20 and 5%
nonfat milk) and incubated overnight at 4°C with antibod-
ies specific for Stat3 (monoclonal, 1:2000, Cell Signaling)
and phospho-Stat3 (monclonal, 1:1000; Cell Signaling),
C/EBP- (polycolonal, 1:1000, Cell Signaling), C/EBP-
(polyclonal, 1:1000, Novus Biologicals), and HIF-1
(monoclonal, 1:1000, BD Transduction Lab, Research
Triangle Park, NC). Blots were washed and incubated
with horseradish peroxidase conjugated to goat anti-
mouse or goat anti-rabbit antibodies (1:2000, Bio-Rad,Hercules, CA) for 1 hour at room temperature and devel-
oped by enhanced chemiluminescence reagents (Pierce
Biotechnology). Histone H1 (monoclonal, 1:4000; Santa
Cruz Biotechnology, Santa Cruz, CA) was used as load-
ing control for the nuclear compartment.
Survival Analysis
Association between C/EBP-, C/EBP-, and STAT3 ex-
pression and survival were examined using the log rank
test to compare the upper and lower quartiles of gene-
centric profiles. Survival was taken as “days to death” for
uncensored patients and “days to last follow-up” for right-
censored patients.
Reporting
All qualitative analysis were repeated three times. Quan-
titative data are expressed as mean  SEM. Significance
was defined as P  0.05.
Results
Extent of Necrosis and Angiogenesis Vary within
Frozen TCGA GBM Samples
We investigated potential correlation of microenviron-
mental features in GBM with gene expression and
genomic patterns, and we primarily focused on the two
dominant pathological findings of GBM: necrosis and
angiogenesis.11,19,20 Two sources of data were used as
measures of the degree of necrosis and angiogenesis in
frozen section slides of TCGA samples analyzed for qual-
ity assurance before molecular analysis. As a primary
source, we downloaded digitized images from all 177
available frozen section slides, corresponding to 99 sam-
ples and 91 patients, and marked up images for degree
of necrosis and angiogenesis using a computer-human
interface (Figure 1). The percentage necrosis varied from
0 to 84.7% with a mean of 13.6  1.9%. The degree of
angiogenesis varied from 0 to 13.7% with a mean of
1.4  0.2%. There was a weak positive relationship be-
tween the percent necrosis and angiogenesis within each
sample (Spearman’s rho  0.29).
As a secondary source, we used annotations of 293
GBMs, which were recorded by TCGA neuropathologists
who reviewed frozen section slides for quality assurance.
Percent necrosis was recorded as a visual estimate of total
tissue area involved. Angiogenesis was recorded only as
“present” or “absent,” and was not useful in our analysis.
Percent necrosis in these cases varied from 0 to 87.5% with
a mean of 14.5  1.6%. Among 70 samples with overlap
between the two sources of data, there was strong agree-
ment on percent necrosis (Spearman’s rho  0.71).
Mesenchymal GBMs Are Enriched with
Samples with High Necrosis
To determine whether there was a correlation between
transcriptional class and extent of necrosis or angiogen-
2112 Cooper et al
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these features. In the set of 85 GBMs manually marked
for necrosis with associated molecular data, we found
that the mesenchymal class was significantly enriched
with samples that had a high degree of necrosis (31% of
cases with 25% necrosis) compared to the other three
tumor subtypes (0 cases with 25% necrosis) (Figure
1C). The mesenchymal class also had a higher mean
percent necrosis (21.5  4.5%) than the other three
classes combined (6.9  0.9%; one-way analysis of vari-
ance; P  8.7  104). Extent of angiogenesis was not
significantly associated with GBM subtype, yet all ex-
treme outliers (angiogenesis 8%) were mesenchymal
(Figure 1F). We validated these findings using the set of
GBMs, which were visually estimated for necrosis by
TCGA neuropathologists (291 samples; not shown). In
this set, the mesenchymal class was also significantly en-
riched in samples with high necrosis compared to other
classes (one-way analysis of variance; P  6.9  105).
Because genetic alterations may play a role in the
gene expression class and could be related to the extent
of necrosis and angiogenesis, we determined if the level
of necrosis was related to TP53, PTEN, EGFR, NF1, or
IDH1mutations, EGFR or PDGFRA amplification, CDKN2A
deletion or G-CIMP status. In analysis of 189 samples
with DNA methylation data, we found that low necrosis
was significantly associated with G-CIMP status (two-
way t-test; P  0.0064), but not with the proneural class
as a whole. Analysis of a more limited set of 114 cases
with mutation data did not reveal a significant association
among IDH1 mutants and wild-type cases. No other sig-
nificant correlations were noted between angiogenesis
and necrosis, and frequent genetic alterations in GBM
(TP53, PTEN, EGFR, or NF1 mutations, EGFR or PDGFRA
amplification, CDKN2A deletion).
Next we compared extremely necrotic mesenchymal sam-
ples to GBMs from other transcriptional classes to determine
whether they had a distinctive spectrum of genomic altera-
tions.6 Because thosemesechnymalGBMswith40%necro-
Table 1. Mutation and Copy Number Alterations in Highly
Necrotic GBMs Compared to Low Necrosis,
Nonmesenchymal GBMs
Genes mutated
High necrosis,
MS; n (%)
Low necrosis,
non-MS; n (%)
TP53 1/4 (25) 15/70 (21.4)
PTEN 0/4 (0) 14/70 (20.0)
NF1 1/4 (25) 3/70 (4.3)
EGFR 1/4 (25) 14/70 (20)
ERBB2 0/4 (0) 5/70 (7.1)
RB1 0/4 (0) 4/70 (5.7)
PIK3R1 0/4 (0) 10/70 (14.3)
PIK3CA 1/4 (25) 3/70 (4.3)
IDH1 0/4 (0) 7/70 (10.0)
Copy number alterations n (%) n (%)
EFGR amplification 3/4 (75) 50/66 (75.8)
PDGFRA amplification 1/4 (25) 12/66 (18.2)
CDKN2A deletion 2/4 (50) 2/66 (63.6)
Frequency of mutations and copy number variation from the TP53, RB,
and receptor tyrosine kinase pathways in MS samples with more than
40% necrosis and samples from all other transcriptional classes.
GBMs, glioblastomas; MS, mesenchymal; RB, retinoblastoma.sis represented statistical outliers (Figure 1C), we compared
this subset to all nonmesenchymal GBMs. These outlying ne-
crotic mesenchymal GBMs did not harbor a particular set of
genetic alterations when compared to samples in the other
three transcriptional classes (Table 1). Thus, there was not a
defining set of genetic alterations associated with the highly
necrotic mesenchymal cases.
Extent of Necrosis Is Correlated with the
Expression of Master Regulators of the
Mesenchymal Transition and Specific
Canonical Signaling Networks
Next we used significance analysis of microarrays Cox
proportional hazards modeling of gene expression from
the HT-HGU133A platform to identify mRNAs significantly
associated with the extent of necrosis and/or angiogen-
esis using a false discovery rate cutoff of 5%. Signifi-
cance analysis of microarray analysis of necrosis extent
identified 2422 significantly correlated genes. Gene lists
are provided in Supplemental Tables S7 and S8 (avail-
able at http://ajp.amjpathol.org). Among the positively
correlated genes were factors identified as master regu-
lators of the mesenchymal tumor class, including
C/EBP- (ranked 4), C/EBP- (ranked 60), STAT3 (ranked
213), FOSL2 (ranked 10), bHLHE40 (ranked 221), and
RUNX1 (ranked 366) (Table 2).8 The master regulator
ZNF238 (ranked 363), identified as a repressor, was
listed among the negatively correlated genes (see Sup-
plemental Table S7 at http://ajp.amjpathol.org).
We further analyzed gene expression and the extent of
necrosis specifically within the mesenchymal expression
class (28 cases), splitting these into those with 15%
necrosis (16 cases) and those with 15% (12 cases).
Analysis of the 2422 genes correlated with necrosis iden-
tified 49 probes significantly upregulated in the high ne-
crosis group, including C/EBP- (ranked 3) and matrix
metalloproteinase-19.
Because the master regulators of the mesenchymal tran-
scriptional class were defined using data from Phillips et al4,
we determined whether these transcription factors were
also enriched within the mesenchymal class defined by
TCGA data.5 We found that C/EBP-, C/EBP-, STAT3,
FOSL2, RUNX1, and bHLHE40 were all significantly up-
Table 2. Master Transcriptional Regulators of the Mesenchymal
Transition are Strongly Associated with Extent of
Necrosis in TCGA GBMs
Gene symbol
q value
(corrected P value)
Rank among
2422 genes
C/EBP- 0.0017 4
FOSL2 0.0017 10
C/EBP- 0.0017 60
STAT3 0.0017 213
bHLHE40 0.0017 221
ZNF238 0.0091 363
RUNX1 0.0017 366
GBMs, glioblastomas; TCGA, The Cancer Genome Atlas.regulated when comparing mesenchymal tumors to other
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most highly enriched, followed by FOSL2, RUNX1,
bHLHE40, C/EBP-, and STAT3 (Table 3). The repressor
ZNF238 was also significantly down-regulated in the mes-
enchymal class. However, in comparison of transcription
factor expression among individual expression classes, we
noted that C/EBP-, STAT3, and ZNF238 showed similar
expression in classical and mesenchymal tumors (Table 3).
Genes that were significantly associated with the ex-
tent of necrosis were submitted to IPA to identify pathways
enriched in gene sets associated with necrosis (Figure 3). IPA
analysis of genes identified significantly enriched canonical
pathwaysassociatedwith acute response,migration, invasion,
Figure 2. Distribution of CEBP- and STAT3 gene expression levels within
The Cancer Genome Atlas gene expression classes. Each dot represents one
glioblastoma (GBM) sample. Compared to the neural, proneural, and classi-
cal gene expression classes combined, the mesenchymal class showed en-
richment for tumors with high CEBP- (A) and STAT3 (B). All six activators
and the repressor (ZNF238) are significantly differentially expressed when
comparing mesenchymal to non-mesenchymal GBMs (two-way t-test, un-
equal variances; see Table 3).
Table 3. Transcriptional Regulators of the MS Transition are Diff
P value C/EBP- C/EBP- STAT3
MS vs non-MS 2.5 1029 4.12  1016 1.33  10
MS vs CL 8.27 1021 0.0115 0.0238The differential expression of C/EBP-, STAT3, and ZNF238 was less signific
GBM, glioblastoma.thrombosis, cell survival, and hypoxia including Rac (P  
106), Rho (P  1.1  106), PI3K/AKT (P  4.1  106),
complement system (P  1.3  104), NFB (P  1.8 
104), IL-6 (P  4.3  105), ERK/MAPK (P  4.9  104),
JAK/STAT (P  0.0083), and hypoxia signaling (P  0.015).
Significance analysis of microarray for angiogenesis identified
only 18 significantly correlated genes, none of which were
mesenchymal master regulators (see Supplemental Table S8
at http://ajp.amjpathol.org). The intersection of the necrosis
and angiogenesis correlated gene sets contained 8 signif-
icantly correlated genes, including the positively correlated
gene FN1. We attribute the lack of significant findings on
angiogenesis-related genes to the limitations of the meth-
ods used for measurement. Given that the surface area of
angiogenesis represents only a small percentage of the
total tissue (4% for the large majority of samples), mean-
ingful correlations between angiogenesis and gene expres-
sion were not observed, most likely due to low signal-to-
noise ratios in the microarray experiments and imaging
quantifications.
We also performed a pathway analysis on genes dif-
ferentially expressed in high and low necrosis mesenchy-
mal GBMs. Within this set, IPA identified significantly
enriched canonical pathways associated with inflamma-
tion, cell death, and hypoxia, including IL-6 (P  1.4 
104), IL-8 (P 0.0013), and hypoxia-inducible factor-1
(P  0.0029) (Figure 3).21,22
High Co-Expression of C/EBP-, C/EBP- and
STAT3 Is Associated with Poor Prognosis
To determine whether expression of master regulators of
the mesenchymal transition was correlated with clinical
outcome, we used TCGA data to compare the survival of
patients with high expression (upper quartile) to those
with low expression (lower quartile) of C/EBP-, C/EBP-,
and STAT3 (Figure 4). We examined the impact of indi-
vidual gene expression, as well as their co-expression.
GBMs with high expression of C/EBP- were associated
with a significantly shorter survival (50% survival, 11
months) than those with low expression (50% survival, 14
months) (log rank test, P  0.0071). High expression of
C/EBP- showed a trend toward shorter survival (log rank
test, P 0.0564), whereas high expression of STAT3 was
significantly associated with a shorter survival (P  5.73 
104) (not shown). The co-expression of high C/EBP-,
C/EBP-, and STAT3 was associated with a substantially
shorter survival (50% survival, 12 months) compared to
those that showed all low expression (50% survival, 21
months) (log rank test, P  0.0021).
lly Expressed in MS and Non-MS GBM
FOSL2 bHLHE40 RUNX1 ZNF238
.27  1022 6.67  1016 1.89  1018 5.85  1015
.49  1013 3.89  106 9.80  109 0.0825erentia
9 5
8ant when comparing mesenchymal (MS) and classical (CL) tumors.
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to Mesenchymal Transcriptional Signature
Molecular classes identified by Verhaak et al5 are defined
purely by transcription and are characterized by the formation
of clusters in transcriptional space. To probe the relationship
between necrosis on transcriptional class, we compared the
extent of necrosis with distance to a characteristic mesenchy-
mal gene expression signature in transcriptional space.14 We
first identified a set of 250 genes that distinguish the mesen-
chymal class using a t-statistic to rank and select probes withthe greatest differential expression between mesenchymal
and nonmesenchymal samples. Expression of this gene set
was averaged over all mesenchymal samples to calculate a
representative mesenchymal signature. Then we calculated
the distance in terms of gene expression for each nonmesen-
chymal sample to themesenchymal signature asameasure of
similarity to themesenchymal class. Amongnonmesenchymal
GBMs, we found that the distance to the mesenchymal signa-
ture was inversely related to the extent of necrosis (Figure 5).
Using the mark-up data for necrosis, we found an overall
Figure 3. Ingenuity pathway analysis (IPA) identified critical ex-
pression networks containing genes that are significantly correlated
with the extent of necrosis in The Cancer Genome Atlas (TCGA)
glioblastoma (GBM) samples from all subclasses (A and B). The
STAT3 network was among the most closely associated with necrosis
(A). The C/EBP gene network was also highly correlated with the
extent of necrosis and demonstrates the central importance of IL-6.
(B). Gene networks that were differentially expressed between mes-
enchymal GBMs with high (15%) and low extent of necrosis
(15%) included those that were centered around CEBP- and were
strongly associated with upregulated IL-8 signaling (C).correlation of 0.50 among all nonmesenchymal samples,
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0.31 in neural samples. This trend was verified in the visually
estimated necrosis dataset, which uncovered correlations of
0.27 among nonmesenchymal samples,0.24 in proneural
samples, 0.31 in classical samples, and 0.32 in neural
samples. Using the mean distance of mesenchymal samples
to the mesenchymal signature as a baseline (14.8 standard
units), we found that many necrosis-rich nonmesenchymal
samples are remarkably close to the mesenchymal class.
Thus, the gene expression signatures of nonmesenchymal
GBMs became more similar to the mesenchymal signature
with increasing levels of necrosis.
We also found that 94% of the 250 characteristic mes-
enchymal probes were present in the necrosis-correlated
gene set (average rank, 544), suggesting that the with themost distinguishing mesenchymal class genes are also
significantly correlated with necrosis. Overall, these data
suggest that the extent of necrosis strongly impacts the
expression of genes that define the mesenchymal class.
Macrophage Infiltrates Are Not Associated with
Mesenchymal Class or Master Regulators
Weexploredpotentialmicroenvironmental explanations for the
association between necrosis and master transcriptional reg-
ulators (C/EBP-, C/EBP-, and STAT3).8 We considered
whether macrophage infiltrates might be responsible, be-
cause C/EBP-, C/EBP-, and STAT3 are expressed by in-
flammatory cells; IPA identified a pro-inflammatory signature
Figure 4. Glioblastomas (GBMs) with high ex-
pression of C/EBP- (upper quartile) were asso-
ciated with a significantly shorter survival (50%
survival, 11 months) than those with low expres-
sion (50% survival, 14 months) (log rank test P
0.0071), and high co-expression of C/EBP-,
C/EBP-, and STAT3 was associated with a
shorter survival (50% survival, 12 months) than
those that had low expression of all three (50%
survival, 21 months) (log rank test P  0.0021).
Figure 5. Influence of necrosis on transcriptional
distance to mesenchymal class signature. Euclid-
ean distance to the mesenchymal class signature
was computed for all nonmesenchymal samples,
and the Spearman correlations between transcrip-
tional distance and extent of necrosis were com-
puted. The median distance between mesenchy-
mal samples and the mesenchymal signature
(indicated in green) is 14.8. There is an inverse
relation between the extent of necrosis and the
distance to the mesenchymal gene signature.
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trates might increase with the extent of tissue damage.23–25
Using the set of 112 TCGA GBMs reviewed by a panel of
TCGA neuropathologists and annotated for macrophage infil-
trate as 0 (90 cases), 1 (21 cases), or 2 (1 case) for
molecular correlates, we noted an enrichment of GBMs with
macrophage infiltrates (1 or 2) within the proneural tran-
scriptional class (Fisher’s exact P  0.026), but not in the
mesenchymal class.Whenwecompared thegeneexpression
of C/EBP-, C/EBP-, STAT3, FOSL2, bHLHE40, and RUNX1
in those cases with macrophage infiltrates (1 or 2) to those
without, we did not find any statistically significant differences.
To explore the pattern and degree of macrophage infiltrate
in GBMs, especially related to necrosis and to the expression
of C/EBP-, C/EBP-, and STAT3, we performed IHC on 10
cases selected to contain infiltrating glioma, high gradeglioma
with necrosis and angiogenesis, and adjacent non-neoplastic
brain. Double immunostaining was used to estimate the per-
centage of CD68 or CD163macrophageswithin the tumor
sample and to determine the strength of transcription factor
expression in this cell population (Figure 6). The percentage of
macrophages within GBM samples varied from 5% to 24%
(mean, 14.5%  2.2%), whereas the large majority of cells
were neoplastic (70% in all cases).Macrophageswere seen
Figure 6. Double immunohistochemistry for macrophages (CD163, red) and C
represent a minority of the cells in GBM and are scattered throughout the tumo
and C/EBP- (D) expression was increased in perinecrotic pseudopalisading ce
and STAT 3 was uniform in tumor cells and did not show microregional variati
layers from necrosis (A, arrowhead). Only rare cells away from necrosis show
GBM cells (F). U87MG cells grown for 24 hours under hypoxia (H) (1% O2) sh
protein expression under normoxia (N) (21%O2). Protein expression of C/EBP-
and hypoxia. pSTAT3 was expressed exclusively in the nucleus and did not show
as a positive control for hypoxic conditions, with histone H1 serving as a loadiclustered around blood vessels, within brain tumor stromaindividually, and in small collections within necrotic foci (Figure
6). Pseudopalisading cells directly surrounding necrosis were
not enrichedwithmacrophages, consistent with our prior stud-
ies.26 The extent of necrosis within the tissue sections of these
GBMs varied from 5% to 59% (mean, 24.0%  5.2%). We
found that the expression of STAT3 and pSTAT3 was consis-
tently strong in macrophages (2), whereas the expression of
both C/EBP- and C/EBP- was moderate (1). There was a
weak positive correlation between extent of necrosis and per-
cent macrophages within these 10 GBM samples (Spear-
man’s rho 0.33). Thus, C/EBP-, C/EBP-, and STAT3 were
expressed by macrophages, but these represented only a
minor percentage of total cells within GBM samples and ex-
hibiting only a modest relationship with the extent of necrosis.
C/EBP- and C/EBP- Are Strongly
Upregulated in Hypoxic, Perinecrotic
“Pseudopalisading” Cells in GBM
In our IHC study of C/EBP-, C/EBP-, STAT, and
pSTAT3, we noticed a consistent pattern of protein ex-
pression of C/EBP- and C/EBP- that strongly correlated
with the presence and degree of necrosis (Figure 6).
brown) in human glioblastoma (GBM) samples demonstrates that macrophages
(arrow) but do not accumulate around necrosis (A, asterisk). C/EBP- (A–C)
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GBMs.19 These cells surrounding the necrosis are hy-
poxic and express angiogenic factors such as vascular
endothelial growth factor and IL-8, proteases, and coag-
ulation factors.16,27 C/EBP- was specifically expressed
in the 2 to 5 cell layers directly surrounding necrosis, and
it was exclusively nuclear in location. C/EBP- was not as
strongly upregulated in perinecrotic cells, yet extended a
greater distance from necrosis, and displayed nuclear
and cytoplasmic staining. In regions of neoplasm be-
tween foci of necrosis, protein expression was noted only
infrequently (5% of cells) and weakly (0 to 1) for both
C/EBP- and C/EBP-. There was no significant protein
expression in neurons or glia within the adjacent non-
neoplastic brain tissue. STAT3 and pSTAT3 did not dem-
onstrate a perinecrotic expression pattern. Rather, these
proteins were moderately to strongly expressed by the
majority of neoplastic cells (2 to 3) and did not show
substantial microregional variation. STAT3 was ex-
pressed in both the cytoplasm and nucleus, whereas
pSTAT3 was predominantly nuclear.
C/EBP- Is a Hypoxia-Inducible Transcription
Factors in Vitro
Given the strong expression of C/EBP- and C/EBP- in
hypoxic pseudopalisading cells, we investigated whether
these factors were hypoxia-inducible.28 We exposed the
human GBM cell line U87MG to either 20% O2 (normoxia)
or 1% O2 (hypoxia) for 24 hours and measured the ex-
pression of C/EBP-, C/EBP-, STAT3, pSTAT3, and
HIF-1 by Western blot. We noted upregulation of
C/EBP- under hypoxic conditions by U87MG (Figure 6).
Similar to IHC staining, expression was restricted to the
nuclear compartment. C/EBP-, STAT3, and pSTAT3
were not induced by hypoxia in this cell line.
Discussion
This study represents the first correlative investigation of
TCGA molecular data with tumor microenvironmental fea-
tures. One of its key strengths is the use of the frozen
section slides from TCGA samples, which are immedi-
ately adjacent to the tissue used to generate correspond-
ing molecular data. Frozen sections do not allow detailed
visualization of cytologic fine structures, although, in the
present case they greatly improved the ability to detect
molecular correlates of microenvironmental features by
minimizing sampling error. Using this approach, we
found that the extent of necrosis within TCGA GBM tissue
samples was associated with a specific transcriptional
class defined by Verhaak et al.5 The mesenchymal tran-
scriptional class was highly enriched with tumor samples
that contained greater levels of necrosis than those in the
proneural, neural, and classical classes. In contrast, a
transcriptional class of GBM associated with low levels of
necrosis was not identified.
Genes that showed among the strongest correlations
between their expression and the extent of necrosis in-
cluded transcription factors that were recently identified asregulators of the mesenchymal transition, C/EBP-,
C/EBP-, STAT3, FOSL2, bHLH-B2, and RUNX1.8 Using a
network analysis algorithm and gene expression data from
Phillips et al4, these factors were found to account for 74%
of the expressed genes within the mesenchymal gene sig-
nature.4,8 Consistent with their critical role in determining the
transcriptional signature of the mesenchymal class, our
findings using TCGA data demonstrated that C/EBP-,
C/EBP-, STAT3, FOSL2, bHLH-B2, and RUNX1 were
highly overexpressed in the mesenchymal GBMs as
compared to the other three classes.
Explanations for the clustering of GBM samples into
specific expression classes are currently incomplete, yet
there are likely multiple contributing factors. It is clear that
epigenetic changes and genetic alterations, including
mutations and copy number alterations, have an impact
on the transcriptional signatures. For example, GBMs
with IDH1mutations and/or the G-CIMPmethylator phe-
notype are nearly all proneural, whereas those with NF1
deletions or mutations are enriched in the mesenchymal
class.5,7 Those tumors with genetic alterations in TP53,
EGFR, PDGFRA, PTEN, and CDK2A, however, are found
in multiple transcriptional classes. We did not find an
association between these common genetic alterations
and the extent of necrosis in GBM that might explain the
relation of high necrosis and mesenchymal class. The
mesenchymal GBMs with the highest levels of necrosis
had a similar spectrum of alterations in these genes as
those with low necrosis in all transcriptional classes.
These findings indicate that similar genetic alterations
can be associated with dissimilar transcriptional signa-
tures and suggest that some other biological parameters
associated with necrosis (hypoxia, low pH, immune cell
infiltrates, and so forth) may impact transcriptional class
independently.
Among the transcription factors identified by Carro
et al8, as key mediators of the mesenchymal transition, it
was demonstrated by in silico and in vitro approaches that
C/EBP-, C/EBP-, and STAT3 were master transcrip-
tional regulators and together controlled the others in a
hierarchical manner. These findings were compelling, yet
they did not demonstrate genetic or pathophysiological
triggers or explore microregional distributions that may
be important to tumor progression.
Because C/EBP-, C/EBP-, and STAT3 are known for
their roles in inflammation, we considered whether their
correlation with necrosis in GBM was due to expression
by macrophages, which are infrequent compared to neo-
plastic cells, yet increase in numbers with necrosis.23–25
In our analysis of TCGA GBMs annotated by a panel of
neuropathologists, we found no association between the
degree of macrophage infiltrate and the mesenchymal
transcriptional class. Neither was there a relationship
noted between degree of macrophage infiltrate and the
expression of C/EBP-, C/EBP-, and STAT3. In our
IHC analysis, macrophages showed a moderate level
of expression of these transcription factors, yet this cell
type accounted for a minor percentage of total cells in
GBM specimens, with the vast majority of cells being
neoplastic. Thus, the expression of C/EBP-, C/EBP-,
and STAT3 by macrophages may contribute to the
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ion. In addition to macrophages, there may be other
types of non-neoplastic cells that could contribute to
the mesenchymal signature and are deserving of fur-
ther investigation.
We also explored whether the necrosis that emerges in
GBM could account for the upregulation of mesenchymal
transcription factors. Necrosis and its associated severe
hypoxia are critical pathophysiological features that arise
in the microenvironment as astrocytomas progress to
GBM and are strongly associated with aggressive bio-
logical behavior.19,22,29 The dense collection of pseu-
dopalisading cells that surround necrotic foci in GBM are
hypoxic, express HIF-1, and secrete pro-angiogenic
factors including vascular endothelial growth factor and
IL-8, which lead to an angiogenic response that drives
rapid tumor growth.19,26,30 We noted that the expression
of C/EBP- was strong and highly specific within these
pseudopalisading cells in GBM samples. C/EBP- was
also seen in peri-necrotic cells, but its upregulation was
not as dramatic or specific. Neoplastic cells that were not
surrounding necrosis showed only infrequent expression
of C/EBP- and C/EBP-. Given this pattern, it would be
expected that C/EBP- and C/EBP- gene and protein
expression would correlate with the degree of necrosis in
GBMs, as noted in our analysis. STAT3 expression did
not show a spatial association with necrosis in GBM tis-
sue sections and its correlation with necrosis by gene
expression analysis could not be explained morphologi-
cally.
Given the correlation between gene expression signa-
tures and degree of necrosis, it could be argued that the
transcriptional program gives rise to tumors that are more
prone to develop necrosis, or that the development of
necrosis causes a change in transcriptional signature.31
We find it more likely that necrosis impacts the transcrip-
tional class. Two of the master transcriptional regulators,
C/EBP- and C/EBP-, which sit atop the hierarchy of
critical signaling networks in the mesenchymal transition,
were found to be specifically expressed by perinecrotic
cells in human GBM samples, and C/EBP- was upregu-
lated by hypoxia in vitro, suggesting that the emergence
of necrosis leads to upregulation of these factors. Among
the two C/EBP isoforms, C/EBP- was the most tightly
associated with the mesenchymal transcription class and
with the extent of necrosis within the mesenchymal GBM
samples. C/EBP- also showed the most specific expres-
sion in pseudopalisading cells in GBM samples and was
hypoxia-inducible in vitro. Surprisingly, C/EBP- was not
upregulated by hypoxia in cell culture, which may indi-
cate that its induction in perinecrotic cells is due to other
physiological factors, such as high pH or regional cyto-
kines. Combined, these data suggest that C/EBP- may
be most critical for the tight association between necrosis
and the mesenchymal gene signature.
Our results imply that GBM transcriptional signatures
are strongly impacted by the development of necrosis
and could evolve within a duration of time as tumors
progress. Nonmesenchymal GBMs were noted to be
more transcriptionally similar to the mesenchymal class
with increasing levels of necrosis, suggesting that theremay be transitions between transcriptional classes that
depend on necrosis and potentially other microenviron-
mental influences. It remains possible that differing tran-
scriptional classes may be found within the same GBM
and depend on the degree of necrosis within the tissue
sampled. These implications deserve further study and
will need to be carefully considered as therapies are
directed toward specific molecular profiles in the future.
Beyond their significance to transcriptional class iden-
tity, it is clear that these master transcriptional regulators
are strong drivers of tumor biology. Within the TCGA
dataset, and including all transcriptional classes, GBMs
with high expression of C/EBP-, C/EBP-, and STAT3
had much shorter survivals than those with low expres-
sion. These data suggest that these master regulators or
their immediate downstream signaling nodes may be ap-
propriate therapeutic targets.
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